EdenTree Asset Management’s Autolus Therapeutics AUTL Stock Holding History

EdenTree Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$477K	Hold	300,000	–	–	0.15%	64
2026 Q1	$414K	Hold	300,000	–	–	0.12%	63
2025 Q4	$594K	Hold	300,000	–	–	0.18%	60
2025 Q3	$486K	Hold	300,000	–	–	0.12%	62
2025 Q2	$684K	Hold	300,000	–	–	0.19%	58
2025 Q1	$462K	Buy	+300,000	New	+$609K	0.16%	61
2023 Q3	–	Sell	-180,000	Closed	-$430K	–	70
2023 Q2	$430K	Buy	+180,000	New	+$427K	0.15%	68

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EdenTree Asset Management's AUTL Position: Q2 2026 in Review

EdenTree Asset Management held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 300,000 shares worth $477K. The position accounts for 0.15% of the portfolio, ranked #64.

EdenTree Asset Management first reported a position in AUTL in Q2 2023 and has held it in 7 quarters since. The position peaked at $684K in Q2 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

EdenTree Asset Management held 300,000 shares of Autolus Therapeutics worth $477K as of Q2 2026.
EdenTree Asset Management left its Autolus Therapeutics share count unchanged in Q2 2026.
Autolus Therapeutics made up 0.15% of EdenTree Asset Management's portfolio in Q2 2026, its #64 holding.
EdenTree Asset Management first reported a position in Autolus Therapeutics in Q2 2023 and has held it in 7 quarters since.
EdenTree Asset Management's Autolus Therapeutics position peaked at $684K in Q2 2025.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on EdenTree Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.